The contract allows Qilu Pharmaceutical to use the antibody, which was developed through Biocytogen’s RenNano platform, in its research and development (R&D) activities focused on neuroscience therapeutics. It
The deal allows Novartis to exercise multiple options for exclusive global rights to develop subcutaneous versions of several of its products employing the berahyaluronidase alfa enzyme, also known
The agreement will see Aitia apply its REFS technology to build Gemini Digital Twins (GDTs) of neurological conditions to identify potential new therapeutic targets and biomarkers. Ono Pharmaceutical
The partnership aims to integrate Weave Bio’s AI tools with Takeda’s regulatory experience to streamline workflows within the regulatory process. The joint effort began with the use of
This marks the first FDA-approved treatment for ET in nearly 30 years. The approval is based on data from the global Phase III SURPASS ET trial, which demonstrated
These proceeds will support the planned and ongoing studies of Kazia’s lead investigational therapy, paxalisib, in triple-negative breast cancer, hormone receptor positive/human epidermal growth factor receptor 2 negative
The agreement arises as part of BioXcel Therapeutics’ voluntary Chapter 11 proceedings in the US Bankruptcy Court for the District of Delaware, initiating a court-supervised sale of the
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of 30 April 2027. Also known as bimatoprost grenod or NCX 470, K-911 is
The round was led by an undisclosed strategic investor. New investor RA Capital Management also participated, along with existing investors that included HanKang Capital, Qiming Venture Partners and
The designation covers CMT as a whole and is not restricted to specific subtypes. The RPDD programme seeks to promote the development of therapies for rare, serious or
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.